GlassScriptPhysician profile
Joseph J Rousher
NPI 1568738193
$2,319.09
in general payments reported to CMS, 2019-2025
26 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $756 · 2020: $349 · 2021: $313 · 2022: $441 · 2023: $143 · 2024: $181 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $460.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $469.95 | 2021-2025 | Ubrelvy |
| Pfizer INC. | $238.09 | 2019-2025 | |
| Glaxosmithkline, LLC. | $203.87 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.66 | 2019 | |
| Merck Sharp & Dohme LLC | $114.88 | 2019-2023 | Vaxneuvance, Vaqta, Gardasil 9 |
| Esperion Therapeutics, INC. | $101.03 | 2020-2021 | |
| Amgen INC. | $98.94 | 2019-2024 | Krystexxa |
| Sunovion Pharmaceuticals INC. | $98.13 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.29 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $96.20 | 2019-2022 | |
| Lilly USA, LLC | $94.46 | 2019-2024 | Mounjaro, Zepbound |
| Novo Nordisk INC | $88.43 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $88.18 | 2020-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $78.81 | 2019-2022 | |
| Amarin Pharma, INC. | $62.24 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Reapplix INC. | $52.62 | 2025 | 3c Patch Kit - Box |
| Kowa Pharmaceuticals America, INC. | $47.73 | 2019-2020 | |
| Sanofi Pasteur INC. | $32.66 | 2019-2020 | |
| Allergan, INC. | $30.27 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $20.78 | 2023 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.67 | 2023 | Xifaxan, Trulance |
| Abbott Laboratories | $16.19 | 2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $14.45 | 2022 | |
| Novartis Pharmaceuticals Corporation | $12.87 | 2019 | |
| Portola Pharmaceuticals, LLC | $11.37 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Rousher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.